About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Melanoma Clinical Trials in Denver | 253 Studies | Clareo Health

Clinical Trials MelanomaDenver

Melanoma Clinical Trials in Denver

Find 253 clinical trials for melanoma near Denver, Colorado. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Denver

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 141-160 of 253 trials

COMPLETEDPhase 1/28.4 miles

Study of PI-88 in Patients With Advanced Melanoma

NCT00068172

The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.

Cellxpert Biotechnology Corp.88 participantsStarted Jul 2001

Aurora, Colorado, United States

COMPLETEDPhase 38.4 miles

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

Bristol-Myers Squibb387 participantsStarted Apr 2016

Aurora, Colorado, United States • Tampa, Florida, United States • Fridley, Minnesota, United States +54 more locations

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 38.4 miles

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

NCT01721746

The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel

Unresectable or Metastatic Melanoma

Bristol-Myers Squibb405 participantsStarted Dec 2012

Phoenix, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +92 more locations

COMPLETEDPhase 1/28.4 miles

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Endometrial CancerHead and Neck Cancer+11 more

Incyte Corporation444 participantsStarted Jul 2014

La Jolla, California, United States • Los Angeles, California, United States • Sacramento, California, United States +21 more locations

COMPLETEDNA8.4 miles

SunSmart Intervention in Schools

NCT03745872

A prevention study to improve sun exposure behaviors in children after an educational classroom-based intervention.

University of Colorado, Denver76 participantsStarted Sep 2017

Aurora, Colorado, United States

COMPLETED12 miles

Virtual Sun Safe Workplaces Ph I

NCT05146622

Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer. In Phase I, the feasibility of a virtual learning environment (VLE) for distributing our effective Sun Safe Workplaces (SSW) intervention to American employers will be established with input from senior managers and Hispanic and African American outdoor workers and development and evaluation of a prototype of the SSW Works VLE. In Phase II, the full SSW Works will be produced and tested for effectiveness at improving outdoor workers' sun protection in a randomized trial enrolling employers nationwide.

Klein Buendel, Inc.104 participantsStarted Oct 2021

Golden, Colorado, United States

COMPLETEDNA12 miles

Engaging Moms on Teen Indoor Tanning Through Social Media

NCT02835807

A sample of mothers in Tennessee are recruited to a group-randomized pretest-posttest controlled trial evaluating the effect of a social media campaign to decrease mothers' permissiveness for daughters to indoor tan. The primary outcomes is mothers' permissiveness for indoor tanning by daughters. Secondary outcomes are mother's indoor tanning prevalence and their support for stricter bans on indoor tanning by minors.

Klein Buendel, Inc.1,607 participantsStarted Jun 2015

Fort Collins, Colorado, United States • Golden, Colorado, United States • Storrs, Connecticut, United States +1 more locations

COMPLETEDNA63 miles

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

NCT00297895

Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.

Saint John's Cancer Institute1,939 participantsStarted Sep 2004

San Diego, California, United States • Santa Monica, California, United States • Colorado Springs, Colorado, United States +60 more locations

TERMINATEDPhase 1334 miles

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699

This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHodgkin Disease+17 more

Seagen Inc.159 participantsStarted Feb 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +16 more locations

COMPLETEDPhase 2357 miles

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

NCT01127451

The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.

Stage IIIC MelanomaStage IV Melanoma

Eisai Inc.75 participantsStarted Jun 2010

Encinitas, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +7 more locations

TERMINATEDPhase 3370 miles

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508

The primary objectives of the Phase 1b part of the study are to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with previously untreated, unresectable, stage IIIB to IVM1c melanoma. The primary objective of Phase 3 are to evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded independent central review using modified Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) and overall survival (OS).

Amgen713 participantsStarted Dec 2014

Birmingham, Alabama, United States • Mobile, Alabama, United States • Beverly Hills, California, United States +158 more locations

COMPLETEDPhase 1371 miles

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

MelanomaCervical CarcinomaPancreatic Carcinoma+20 more

Xencor, Inc.78 participantsStarted May 2019

Encinitas, California, United States • La Jolla, California, United States • La Jolla, California, United States +25 more locations

COMPLETEDPhase 1/2371 miles

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

NCT02404441

The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, PDR001 inhibits the PD-1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells.

MelanomaNon-small Sell Lung Cancer (NSCLC)Triple Negative Breast Cancer+2 more

Novartis Pharmaceuticals319 participantsStarted Apr 2015

Baltimore, Maryland, United States • Boston, Massachusetts, United States • Portland, Oregon, United States +38 more locations

TERMINATEDPhase 3371 miles

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

NCT02288897

This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine (DTIC), temozolomide (TMZ) or intralesional talimogene laherparepvec as determined by Investigator preference and standard of care in the Investigator's country or region. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms.

Cutaneous Melanoma

Provectus Biopharmaceuticals, Inc.20 participantsStarted Apr 2015

San Diego, California, United States • Miami Beach, Florida, United States • Tampa, Florida, United States +20 more locations

TERMINATEDPhase 1576 miles

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

NCT03265080

This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).

Colon Cancer MetastaticHead and Neck Cancer MetastaticMetastatic Non-Small Cell Lung Cancer+2 more

Advaxis, Inc.13 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Orleans, Louisiana, United States +2 more locations

TERMINATED576 miles

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Head and Neck CancerMelanomaHPV-Related Malignancy+5 more

Repertoire Immune Medicines22 participantsStarted May 2021

Scottsdale, Arizona, United States • Ann Arbor, Michigan, United States • Nashville, Tennessee, United States

COMPLETEDPhase 1576 miles

A Study of PLX2853 in Advanced Malignancies.

NCT03297424

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more

Opna Bio LLC49 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Miami, Florida, United States • New York, New York, United States +2 more locations

TERMINATEDPhase 3616 miles

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

NCT03273153

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Advanced BRAFV600 Wild-type Melanoma

Hoffmann-La Roche446 participantsStarted Dec 2017

Tucson, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +118 more locations

COMPLETEDPhase 1795 miles

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

NCT02381314

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

MelanomaNon Small Cell Lung Cancer

MacroGenics24 participantsStarted Mar 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Miami Beach, Florida, United States +7 more locations

COMPLETEDPhase 1830 miles

Safety Study of MGA271 in Refractory Cancer

NCT01391143

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.

Prostate CancerMelanomaRenal Cell Carcinoma+4 more

MacroGenics179 participantsStarted Jul 2011

Los Angeles, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +9 more locations

PreviousPage 8 of 13Next

Other Conditions in Denver

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma